Drug Profile
Research programme: phospholipase A2 inhibitors - Wyeth
Alternative Names: cPLA2α - Wyeth; Ecopladib; PLA-025Latest Information Update: 02 Mar 2011
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Benzoic acids; Sulfonamides
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 15 Oct 2009 Wyeth has been acquired by Pfizer
- 11 Jul 2005 Data presented at the Annual European Congress of Rheumatology (EULAR-2005) have been added to the Asthma and Rheumatic Disorders pharmacodynamics sections
- 05 Apr 2005 Data presented at the 229th American Chemical Society National Meeting (229th-ACS-2005) have been added to the pharmacokinetics and pharmacodynamis sections